MLYS

Mineralys Therapeutics Inc

Apr 02 • 04:00PM ET

26.97

+0.56 2.12 %

Healthcare • Biotechnology • USA • NASD

Mar 31, 10:02 AMACC 2026 meta-analysis showing lorundrostat's strong blood pressure reduction drives MLYS 10.59% higher.

Peers: FENC AKBA EOLS ARDX ESPR PDSB KNSA ACXP CRVS ATHE

| Held by: XBI VTI IWM VXF IBB IWO SCHA VTWO VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.38	Insider Own	25.47%	Shs Outstand	81.54M	Perf Week	14.23%
Market Cap	2.22B	Forward P/E	-	EPS next Y	-1.86	Insider Trans	-6.58%	Shs Float	61.41M	Perf Month	-6.26%
Enterprise Value	1.57B	PEG	-	EPS next Q	-0.48	Inst Own	88.41%	Short Float	14.57%	Perf Quarter	-25.68%
Income	-154.65M	P/S	-	EPS this Y	4.29%	Inst Trans	11.60%	Short Ratio	7.15	Perf Half Y	-32.25%
Sales	0.00M	P/B	3.40	EPS next Y	14.98%	ROA	-35.65%	Short Interest	8.95M	Perf YTD	-25.68%
Book/sh	7.93	P/C	3.38	EPS next 5Y	25.73%	ROE	-36.91%	52W High	47.65 -43.40%	Perf Year	92.64%
Cash/sh	7.97	P/FCF	-	EPS past 3/5Y	-46.34% -101.68%	ROIC	-23.91%	52W Low	10.44 158.33%	Perf 3Y	72.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.04% 7.58%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	34.72%	Oper. Margin	-	ATR (14)	1.85	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	43.76	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.19	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	43.76	EPS Q/Q	59.15%	SMA20	6.22%	Beta	0.70	Target Price	49.38
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-4.14%	Rel Volume	1.31	Prev Close	26.41
Employees	76	LT Debt/Eq	0.00	Earnings	Mar 12 AMC	SMA200	-8.85%	Avg Volume	1.25M	Price	26.97
IPO	Feb 10, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.53% -	Trades		Volume	1,645,165	Change	2.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Initiated	Jefferies	Hold	$15
Jul-10-24	Initiated	H.C. Wainwright	Buy	$30
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Mar-31-26 10:17AM	Immunic appoints biopharmaceutical executive Jon Congleton to board (Proactive) +15.23%
Mar-24-26 08:00AM	Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer (GlobeNewswire)
Mar-16-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-26 08:30AM	Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-12-26 11:06PM	Mineralys Therapeutics Inc (MLYS) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
04:05PM	Loading…
04:05PM	Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-26 04:30PM	Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results (GlobeNewswire)
08:00AM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 (GlobeNewswire)
Feb-26-26 04:05PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-26 07:00PM	Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.45%
Jan-30-26 12:24AM	Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones (Insider Monkey)
Jan-06-26 08:00AM	Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 (GlobeNewswire)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-12-25 11:00AM	Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup (GlobeNewswire)
09:55AM	Loading…
Dec-05-25 09:55AM	Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet (Zacks)
Nov-26-25 04:05PM	Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-25 12:02AM	Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com) +5.87%
Nov-10-25 04:05PM	Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +17.04%
Nov-07-25 06:10PM	Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Nov-05-25 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.66%
Nov-03-25 08:00AM	Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Oct-17-25 09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Sep-30-25 12:34PM	Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups (Insider Monkey)
08:00AM	Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension (GlobeNewswire)
Sep-29-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-16-25 05:41PM	It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps (Motley Fool)
Sep-09-25 12:00PM	What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now? (Zacks) +7.15%
08:23AM	Loading…
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
Sep-05-25 09:00AM	Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need (GlobeNewswire) +5.07%
Sep-04-25 04:01PM	Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.23%
Sep-03-25 11:13AM	Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak (Insider Monkey)
Sep-02-25 09:33PM	Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +86.43%
04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
02:05PM	Why Mineralys Nearly Doubled On AstraZeneca's Hypertension Results (Investor's Business Daily)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-30-25 10:15AM	AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results (Investor's Business Daily)
Aug-18-25 09:55AM	Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade (Zacks) +5.65%
Aug-13-25 03:12AM	Mineralys Therapeutics Inc (MLYS) Q2 2025 Earnings Call Highlights: Pivotal Trial Success and ... (GuruFocus.com)
Aug-12-25 04:05PM	Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-25 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 (GlobeNewswire)
Jul-25-25 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why (Zacks)
09:55AM	Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? (Zacks)
Jul-01-25 02:42AM	Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat (Insider Monkey)
Jun-30-25 11:17AM	Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat (GlobeNewswire)
Jun-17-25 07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria (GlobeNewswire)
May-27-25 08:10AM	Mineralys announces late-breaking presentation of data from Launch-HTN trial (TipRanks)
May-26-25 09:15AM	Mineralys reports outcomes from trial of lorundrostat for hypertension (Clinical Trials Arena)
May-24-25 04:30AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) (GlobeNewswire)
May-22-25 08:50AM	Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going (Zacks)
May-20-25 08:00AM	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection (GlobeNewswire) +5.09%
May-19-25 12:00PM	Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy (Zacks)
May-13-25 07:08AM	Q1 2025 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Mineralys Therapeutics Inc (MLYS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-12-25 04:05PM	Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 08:00AM	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference (GlobeNewswire)
May-05-25 04:05PM	Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 (GlobeNewswire) -7.49%
Apr-23-25 05:23PM	Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) (GlobeNewswire)
Mar-29-25 02:30PM	Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) (GlobeNewswire)
Mar-25-25 11:28AM	Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
08:00AM	Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET (GlobeNewswire)
Mar-18-25 07:58PM	Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? (Insider Monkey) +8.51% +8.55%
04:01PM	Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire)
Mar-17-25 08:00AM	Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo (GlobeNewswire)
Mar-11-25 10:20PM	Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.32%
Mar-10-25 04:01PM	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +42.21%
01:50PM	Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate (Benzinga)
12:57PM	Mineralyss stock soars as hypertension pill scores in two pivotal trials (Clinical Trials Arena)
07:00AM	Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension (GlobeNewswire)
06:30AM	Mineralys shares climb on study data for blood pressure drug (BioPharma Dive)
Mar-07-25 04:01PM	Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET (GlobeNewswire)
Feb-13-25 02:19AM	Q4 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:10AM	Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Highlights: Navigating Increased ... (GuruFocus.com)
Feb-12-25 07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +10.04%
Feb-05-25 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 (GlobeNewswire)
Feb-04-25 08:00AM	Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria (GlobeNewswire)
Jan-09-25 08:29AM	Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials (TipRanks)
Jan-08-25 08:00AM	Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension (GlobeNewswire) -13.71%
Nov-12-24 11:00PM	Mineralys Therapeutics Announces Q3 2024 Results and Updates (TipRanks) -10.32% -6.95%
10:12AM	Q3 2024 Mineralys Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-11-24 04:05PM	Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +6.27%
Nov-05-24 04:05PM	Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.66%
Nov-04-24 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 (GlobeNewswire)
Oct-30-24 08:00AM	Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Oct-22-24 08:00AM	Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 (GlobeNewswire)
Sep-25-24 08:00AM	Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Aug-28-24 08:00AM	Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-24 04:05PM	Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -22.82%
Aug-05-24 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 (GlobeNewswire) -5.66%
Jul-12-24 07:01PM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares (GuruFocus.com) +6.71%
07:01PM	Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares (GuruFocus.com)
Jun-21-24 03:11AM	Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-15-24 02:53AM	Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares (GuruFocus.com)
Jun-14-24 08:00AM	Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors (GlobeNewswire)
02:43AM	Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Jun-03-24 08:00AM	Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-13-24 11:45AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:56AM	MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024 (InvestorPlace)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Congleton Jon	Chief Executive Officer	Mar 31 '26	Sale	26.27	75,000	1,970,522	705,051	Apr 02 06:54 PM
Karydas Daphne	Director	Mar 31 '26	Option Exercise	12.02	3,000	36,060	9,200	Apr 02 06:53 PM
Karydas Daphne	Director	Mar 31 '26	Sale	25.00	3,000	75,000	6,200	Apr 02 06:53 PM
Karydas Daphne	Officer	Mar 31 '26	Proposed Sale	25.00	3,000	75,000		Mar 31 04:18 PM
Congleton Jon	Officer	Mar 31 '26	Proposed Sale	26.27	75,000	1,970,521		Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 27 '26	Buy	23.67	310,700	7,354,269	5,767,221	Mar 31 04:15 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 30 '26	Buy	24.16	58,300	1,408,528	5,825,521	Mar 31 04:15 PM
Rodman David Malcom	Officer	Mar 17 '26	Proposed Sale	25.65	417	10,696		Mar 17 05:04 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Option Exercise	15.44	417	6,438	76,557	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 17 '26	Sale	25.65	417	10,696	76,140	Mar 17 04:51 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Option Exercise	12.39	7,709	95,508	90,198	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Option Exercise	1.08	6,348	6,856	88,837	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 13 '26	Sale	26.26	14,058	369,225	76,140	Mar 16 05:20 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '26	Sale	27.37	6,348	173,748	82,489	Mar 16 05:20 PM
Rodman David Malcom	Officer	Mar 13 '26	Proposed Sale	26.26	14,058	369,225		Mar 13 04:50 PM
Rodman David Malcom	Officer	Mar 12 '26	Proposed Sale	27.37	6,348	173,748		Mar 12 04:13 PM
Rodman David Malcom	Chief Medical Officer	Mar 09 '26	Option Exercise	16.00	2,171	34,736	84,660	Mar 10 05:48 PM
Rodman David Malcom	Chief Medical Officer	Mar 09 '26	Sale	26.84	2,171	58,270	82,489	Mar 10 05:48 PM
Rodman David Malcom	Officer	Mar 09 '26	Proposed Sale	26.84	2,171	58,270		Mar 09 05:15 PM
Rodman David Malcom	Chief Medical Officer	Feb 17 '26	Option Exercise	15.44	417	6,438	44,506	Feb 17 06:56 PM
Rodman David Malcom	Chief Medical Officer	Feb 17 '26	Sale	27.59	417	11,505	44,089	Feb 17 06:56 PM
Rodman David Malcom	Officer	Feb 17 '26	Proposed Sale	27.59	417	11,505		Feb 17 04:05 PM
Rodman David Malcom	Chief Medical Officer	Feb 13 '26	Option Exercise	12.39	7,707	95,484	54,603	Feb 13 07:25 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '26	Option Exercise	1.08	6,349	6,857	56,786	Feb 13 07:25 PM
Rodman David Malcom	Chief Medical Officer	Feb 13 '26	Sale	27.44	14,055	385,732	44,089	Feb 13 07:25 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '26	Sale	28.99	6,349	184,077	50,437	Feb 13 07:25 PM
Rodman David Malcom	Officer	Feb 13 '26	Proposed Sale	27.44	14,055	385,732		Feb 13 04:07 PM
Rodman David Malcom	Officer	Feb 12 '26	Proposed Sale	28.99	6,349	184,077		Feb 12 04:34 PM
Rodman David Malcom	Chief Medical Officer	Feb 09 '26	Option Exercise	16.00	2,171	34,736	52,608	Feb 11 06:58 PM
Rodman David Malcom	Chief Medical Officer	Feb 09 '26	Sale	30.21	2,171	65,586	50,437	Feb 11 06:58 PM
Rodman David Malcom	Officer	Feb 09 '26	Proposed Sale	30.21	2,171	65,586		Feb 09 04:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 20 '26	Option Exercise	15.44	416	6,423	50,853	Jan 20 08:33 PM
Rodman David Malcom	Chief Medical Officer	Jan 20 '26	Sale	32.10	416	13,354	50,437	Jan 20 08:33 PM
Rodman David Malcom	Officer	Jan 20 '26	Proposed Sale	32.10	416	13,354		Jan 20 04:26 PM
Rodman David Malcom	Chief Medical Officer	Jan 13 '26	Option Exercise	12.39	7,709	95,508	69,513	Jan 15 07:07 PM
Rodman David Malcom	Chief Medical Officer	Jan 14 '26	Sale	32.61	11,367	370,645	50,437	Jan 15 07:07 PM
Rodman David Malcom	Chief Medical Officer	Jan 13 '26	Sale	32.75	7,709	252,470	61,804	Jan 15 07:07 PM
Rodman David Malcom	Officer	Jan 14 '26	Proposed Sale	32.61	11,367	370,645		Jan 14 04:00 PM
Congleton Jon	Chief Executive Officer	Jan 12 '26	Sale	32.62	16,236	529,640	639,151	Jan 13 08:43 PM
Levy Adam Scott	CFO and Secretary	Jan 12 '26	Sale	32.14	10,758	345,723	8,638	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 09 '26	Option Exercise	16.00	2,170	34,720	63,974	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '26	Option Exercise	1.08	6,348	6,856	68,152	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '26	Sale	32.32	6,348	205,143	61,804	Jan 13 08:43 PM
Rodman David Malcom	Chief Medical Officer	Jan 09 '26	Sale	33.27	2,170	72,196	61,804	Jan 13 08:43 PM
Rodman David Malcom	Officer	Jan 13 '26	Proposed Sale	32.75	7,709	252,470		Jan 13 04:10 PM
Rodman David Malcom	Officer	Jan 12 '26	Proposed Sale	32.32	6,348	205,143		Jan 12 04:24 PM
Levy Adam Scott	Officer	Jan 12 '26	Proposed Sale	32.14	10,758	345,723		Jan 12 04:23 PM
Congleton Jon	Officer	Jan 12 '26	Proposed Sale	32.62	16,236	529,640		Jan 12 04:23 PM
Rodman David Malcom	Officer	Jan 09 '26	Proposed Sale	33.27	2,170	72,196		Jan 09 04:23 PM
Rodman David Malcom	Chief Medical Officer	Jan 05 '26	Option Exercise	12.26	185,331	2,272,023	254,519	Jan 06 07:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 02 '26	Option Exercise	12.31	67,390	829,667	139,225	Jan 06 07:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 05 '26	Sale	35.02	192,715	6,749,109	61,804	Jan 06 07:20 PM
Rodman David Malcom	Chief Medical Officer	Jan 02 '26	Sale	35.87	70,037	2,511,919	69,188	Jan 06 07:20 PM
Rodman David Malcom	Officer	Jan 02 '26	Proposed Sale	35.71	262,752	9,382,874		Jan 02 05:18 PM
Congleton Jon	Chief Executive Officer	Nov 21 '25	Option Exercise	0.54	24,082	13,004	655,387	Nov 24 05:07 PM
Slingsby Brian Taylor	Director	Nov 20 '25	Sale	43.35	1,000,000	43,350,000	7,903,838	Nov 21 06:07 PM
Catalys Pacific Fund, LP	Affiliate	Nov 20 '25	Proposed Sale	42.12	1,000,000	42,120,000		Nov 20 05:19 PM
Levy Adam Scott	CFO and Secretary	Nov 11 '25	Option Exercise	14.11	105,653	1,490,434	138,920	Nov 13 07:01 PM
Levy Adam Scott	CFO and Secretary	Nov 11 '25	Sale	44.88	119,524	5,363,716	19,396	Nov 13 07:01 PM
Congleton Jon	Chief Executive Officer	Nov 11 '25	Sale	45.44	200,000	9,088,499	631,305	Nov 13 07:01 PM
Karydas Daphne	Director	Nov 13 '25	Option Exercise	10.20	15,000	153,000	15,000	Nov 13 07:01 PM
Karydas Daphne	Director	Nov 13 '25	Sale	45.99	15,000	689,797	0	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 13 '25	Option Exercise	12.15	12,742	154,868	12,742	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 11 '25	Option Exercise	10.20	15,000	153,000	15,000	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 12 '25	Option Exercise	10.20	6,933	70,717	6,933	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 11 '25	Sale	43.98	15,000	659,706	0	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 13 '25	Sale	46.50	12,742	592,503	0	Nov 13 07:01 PM
Gold Alexander M	Director	Nov 12 '25	Sale	46.72	6,933	323,886	0	Nov 13 07:01 PM
Karydas Daphne	Director	Nov 13 '25	Proposed Sale	45.99	15,000	689,796		Nov 13 04:04 PM
Gold Alexander M	Director	Nov 12 '25	Proposed Sale	45.45	34,675	1,576,094		Nov 13 04:03 PM
Levy Adam Scott	Officer	Nov 11 '25	Proposed Sale	44.88	119,524	5,363,716		Nov 12 04:32 PM
Congleton Jon	Officer	Nov 11 '25	Proposed Sale	45.44	200,000	9,088,503		Nov 12 04:28 PM
Levy Adam Scott	CFO and Secretary	Oct 13 '25	Sale	42.01	10,758	451,984	116,865	Oct 15 07:04 PM
Congleton Jon	Chief Executive Officer	Oct 13 '25	Sale	42.67	15,100	644,327	831,305	Oct 15 07:04 PM
Rodman David Malcom	Chief Medical Officer	Oct 15 '25	Sale	43.01	10,369	445,982	71,155	Oct 15 07:04 PM
Rodman David Malcom	Officer	Oct 15 '25	Proposed Sale	43.01	10,369	445,983		Oct 15 04:09 PM
Levy Adam Scott	Officer	Oct 13 '25	Proposed Sale	42.01	10,758	451,983		Oct 14 10:13 AM
Congleton Jon	Officer	Oct 13 '25	Proposed Sale	42.67	15,100	644,326		Oct 14 10:09 AM
Rodman David Malcom	Chief Medical Officer	Sep 15 '25	Sale	36.00	11,367	409,266	81,524	Sep 16 06:54 PM
Rodman David Malcom	Officer	Sep 15 '25	Proposed Sale	36.00	11,367	409,266		Sep 15 04:12 PM
AKKARAJU SRINIVAS	Director	Sep 04 '25	Buy	25.50	588,235	14,999,992	588,235	Sep 08 08:07 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 04 '25	Buy	25.50	1,176,470	29,999,985	5,456,521	Sep 08 05:59 PM
Rodman David Malcom	Chief Medical Officer	Aug 12 '25	Option Exercise	1.08	6,349	6,857	104,256	Aug 14 06:02 PM
Rodman David Malcom	Chief Medical Officer	Aug 13 '25	Sale	12.93	11,365	146,987	92,891	Aug 14 06:02 PM
Rodman David Malcom	Officer	Aug 13 '25	Proposed Sale	12.93	11,365	146,987		Aug 13 05:21 PM
Levy Adam Scott	CFO and Secretary	Jul 30 '25	Sale	14.76	59,925	884,372	132,934	Jul 30 08:12 PM
Levy Adam Scott	CFO and Secretary	Jul 28 '25	Sale	14.04	12,946	181,803	193,666	Jul 30 08:12 PM
Levy Adam Scott	CFO and Secretary	Jul 29 '25	Sale	14.00	807	11,302	192,859	Jul 30 08:12 PM
Levy Adam Scott	Officer	Jul 30 '25	Proposed Sale	14.76	59,925	884,370		Jul 30 05:30 PM
Levy Adam Scott	Officer	Jul 29 '25	Proposed Sale	14.00	807	11,302		Jul 30 09:29 AM
Levy Adam Scott	Officer	Jul 28 '25	Proposed Sale	14.04	12,946	181,804		Jul 28 05:38 PM
Congleton Jon	Chief Executive Officer	Jul 11 '25	Sale	14.51	15,884	230,431	846,405	Jul 15 05:02 PM
Levy Adam Scott	CFO and Secretary	Jul 11 '25	Sale	14.45	10,758	155,454	206,612	Jul 15 05:01 PM
Rodman David Malcom	Chief Medical Officer	Jul 14 '25	Option Exercise	1.08	6,349	6,857	109,273	Jul 15 05:00 PM
Rodman David Malcom	Chief Medical Officer	Jul 14 '25	Sale	14.59	11,366	165,879	97,907	Jul 15 05:00 PM
Rodman David Malcom	Officer	Jul 14 '25	Proposed Sale	14.59	11,366	165,879		Jul 14 04:23 PM
Congleton Jon	Officer	Jul 11 '25	Proposed Sale	14.51	15,884	230,430		Jul 11 04:11 PM
Levy Adam Scott	Officer	Jul 11 '25	Proposed Sale	14.45	10,758	155,454		Jul 11 04:10 PM
Rodman David Malcom	Chief Medical Officer	Jun 12 '25	Option Exercise	1.08	6,348	6,856	113,017	Jun 16 04:03 PM
Rodman David Malcom	Chief Medical Officer	Jun 13 '25	Sale	14.60	11,366	165,931	101,651	Jun 16 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MLYS

Mineralys Therapeutics Inc

Upgrade your Finviz experience